Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01889407|
Recruitment Status : Unknown
Verified July 2013 by Nanfang Hospital of Southern Medical University.
Recruitment status was: Recruiting
First Posted : June 28, 2013
Last Update Posted : April 21, 2015
|Condition or disease||Intervention/treatment|
|Acute Myeloid Leukemia||Drug: Idarubicin|
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||94 participants|
|Observational Model:||Case Control|
|Target Follow-Up Duration:||3 Years|
|Official Title:||Idarubicin Overcomes Multidrug Resistant-1(MDR1) Induced Chemoresistance With Higher Induction Remission Rate and Remission Quality Than Daunorubicin in de Novo Acute Myeloid Leukemia Patients|
|Study Start Date :||August 2013|
|Estimated Primary Completion Date :||July 2016|
|Estimated Study Completion Date :||July 2016|
IA regimen: Patients receive idarubicin (8mg/m2.d) iv drip on days 1-3 and cytarabine (100-200mg/ m2.d) iv drip on days 1-7.
8 mg/m2, iv drip on days 1-3
Patients receive daunomycin (45mg/ m2.d) iv drip on days 1-3 and cytarabine (100－200mg/ m2.d) iv drip on days 1-7.
- complete remission rate [ Time Frame: 3 year ]
- WT1 and MDR1 expression level change after 2 courses of chemotherapy with IA regimen or DA regimen in high-MDR1 expression AML patients. [ Time Frame: 3 years ]
- Identify whether induction therapy with IA regimen has a higher remission quality with AML patients than that of DA regimen in high MDR1 expression AML patients. [ Time Frame: 3 years ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01889407
|Contact: Bing Xu, M.D||13189096353 ext firstname.lastname@example.org|
|Contact: Xutao Guo, M.D||13802426709 ext email@example.com|
|Study Chair:||Bing Xu, M.D||Department of Hematology, Nanfang Hospital, The Southern Medical University|